Zhongzhi Pharmaceutical Holdings Limited provided earnings guidance for the year ended 31 December 2019. For the period, the Group is expected to record a significant increase of approximately over 30% in net profit for the year ended 31 December 2019 as compared with that of the corresponding period in 2018. Such expected increase is mainly due to that certain sales models were transformed in 2019 and the overall control of management fees and sales expenses was strengthened.